A 20-year study found that patients with early-stage prostate cancer who have surgery to remove their tumor do not live longer than those who receive no treatment.
The USPSTF recommends that prostate cancer screenings should be an individual decision.
Antiandrogen therapy with daily bicalutamide to salvage radiation therapy resulted in significantly higher rates of long-term overall survival.
Cases of prostate biopsies resulting in the spread of cancerous cells are rare.
Vasectomy can continue to be a safe method of contraception in men.
A recent cohort study evaluated the risk of developing Alzheimer dementia after ADT in 16,888 men with prostate cancer, 14.2% of whom were treated with ADT.
The analysis of diagnostic characteristics may predict the result of a confirmatory biopsy.
Patients treated with androgen deprivation therapy had a 1.88-times increased rate of developing Alzheimer's disease.
New research suggests that men with low-risk prostate cancer who undergo choose watchful waiting may not receive timely treatment when compared to those undergoing active treatment.
In the United States, the rate of prostate cancer screening is down, and the number of men diagnosed with the disease has also dropped.
Men should regularly be screened for prostate cancer, the leading cause of cancer death for men in the United States.
Higher doses of radiation does not increase survival rates in low-risk prostate cancer.
More targeted efforts needed for prostate-specific antigen screening.
Combination radiation and hormone therapy is more effective than hormone therapy alone for the treatment of prostate cancer.
PCPs should encourage physical activity, smoking cessation, and a healthy diet for PCa survivors.
Multiparametric magnetic resonance imaging reported high accuracy in diagnosing low-risk prostate cancers.
Low adherence rates for prostate cancer care may be target for future quality improvements.
Risk of long-term mortality is lower compared with watchful waiting.
Risk for advanced prostate cancer was 75% lower in men with high levels of 6-sulfatoxymelatonin -- a measure of melatonin breakdown in urine.
Even after adjustment, acute, chronic inflammation linked to lower PCa risk at two-year repeat biopsy.
Potential psychological harm associated with biopsy even in absence of cancer diagnosis
Drinking coffee may lower the risk for prostate cancer recurrence and disease progression.
Aids help men make more informed choices regarding PSA screening, but did not affect actual screening rates.
Men consuming a soy supplement on a daily basis saw no reduction in their chances of prostate cancer recurrence.
Replacing carbohydrates and animal fat with vegetable fat may reduce prostate cancer mortality.
Xofigo has been approved three months ahead of schedule to treat men with metastatic castration-resistant prostate cancer.
Regular, moderate exercise was associated with decreased prostate cancer risk in white, but not black, men.
The FDA has expanded the indication for abiraterone acetate to include treating late-stage castration-resistant prostate cancer before the administration of chemotherapy.
Excess fat around the gluteal region can make performing digital rectal exams in obese patients difficult. How can this challenge be overcome?
Choline C 11 Injection, a PET scan imaging agent, is now available for men with elevated PSA levels after earlier treatment for prostate cancer.